Novan (NASDAQ:NOVN) was upgraded by equities research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Friday.
Several other brokerages have also recently issued reports on NOVN. Zacks Investment Research raised shares of Novan from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Wedbush reissued a “neutral” rating and issued a $6.00 price objective on shares of Novan in a research note on Monday, September 25th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Novan in a research note on Thursday, August 3rd.
Shares of Novan (NOVN) traded down $0.15 on Friday, reaching $4.86. 39,257 shares of the company’s stock traded hands, compared to its average volume of 50,590. Novan has a 12 month low of $3.52 and a 12 month high of $30.90.
WARNING: This piece was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/02/novan-novn-upgraded-at-valuengine.html.
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Novan Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan Inc. and related companies with MarketBeat.com's FREE daily email newsletter.